Agennix Announces Appointment of Regulatory Affairs and Quality Assurance Manager; Leading Biopharmaceutical Company Welcomes New Personnel.HOUSTON--(BW HealthWire)--Aug. 4, 1999-- Agennix Inc. announced today the formal appointment of Dalal Murgai to the position of regulatory affairs Regulatory Affairs (RA), also called Government Affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, energy, and banking. Regulatory Affairs professionals usually have responsibility for the following general areas: An object-oriented language by J.E. Rumbaugh and M.E. Loomis of GE, similar to C++. It is used in implementation of CAD/CAE software. DSM is written in DSM and C and produces C as output. , Agennix's manufacturing partner, and with licensees of Agennix. The announcement was made by Denis Denis, king of Portugal: see Diniz. R. Headon, Ph.D., president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Agennix. Prior to joining Agennix, Murgai spent eighteen months as a regulatory affairs specialist at a biopharmaceutical company in Houston. Also in Houston, she spent two years as a quality assurance scientist and two years as a preclinical biologist for a pharmaceutical product development company. Murgai is a graduate of Texas A&M University. "Ms. Murgai's in-depth experience in dealing with regulatory and quality issues will make a significant contribution to our team," said Dr. Headon. "As we move into commercial production of human lactoferrin lactoferrin (lak´tōfer´in), n an iron-binding protein found in the specific granules of neutrophils where it apparently exerts an antimicrobial activity by withholding iron from ingested bacteria and fungi. to pharma cGMP, Ms. Murgai will bring to Agennix the skills that are essential to the successful development of our technology worldwide." Agennix Inc. is a Houston-based biopharmaceutical company engaged in the research, development and commercialization of a new class of natural anti-inflammatory/anti-infective agents. The company's core underlying technology is built on human lactoferrin, an anti-inflammatory and antimicrobial protein with multiple clinical applications in the treatment of inflammatory and infectious diseases infectious diseases: see communicable diseases. . |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion